Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Critical Care ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical pharmacokinetics of drugs in obesity: an update.Clin Pharm. 1993; 25: 103-114
- Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass.Am J Med. 1988; 84: 1053-1060
- Increased glomerular filtration rate and adrenocortical function in obese women.Int J Obes. 1980; 4: 57-63
- Pharmacokinetics of drugs in obesity.Clin Pharm. 1982; 7: 108-124
- Influence of obesity on drug disposition.Clin Pharm. 1987; 6: 706-714
- Cost effectiveness of a clinical pharmacist on a neurosurgical team.Neurosurgery. 2009; 65: 946-950
- Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarction-related events.Pharmacotherapy. 2009; 29: 761-768
- Impact of a clinical pharmacist in a multidisciplinary intensive care unit.Crit Care Med. 1994; 22: 1044-1048
- Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections.Crit Care Med. 2008; 36: 3184-3189
- Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients.Thromb Res. 2010; 125: 220-223
- Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.J Thromb Haemostasis. 2007; 5: 1191-1194
- Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.Thromb Res. 2008; 123: S58-S61
- The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE).J Thromb Haemost. 2005; 3: 856-862
- Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).Chest. 2008; 133: 141S-159S
- Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin.Obes Surg. 2008; 18: 162-166
- Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.Surg Obes Relat Dis. 2008; 4: 625-631
- Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery.Surg Endosc. 2008; 22: 2392-2395
- The weight-based heparin dosing nomogram compared with a standard care nomogram.Ann Intern Med. 1993; 119: 874
- Optimal therapeutic level of heparin therapy in patients with venous thrombosis.Arch Intern Med. 1992; 152: 1589-1595
- Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.N Engl J Med. 1986; 315: 1109-1114
- Achievement of anticoagulation by using weight based heparin dosing protocol for obese and non-obese patients.Am J Health Syst Pharm. 2001; 15: 2143-2146
- Calculation of heparin dosage in a morbidly obese woman.Clin Pharm. 1989; 8: 65-68
- Optimal weight base for a weight-based heparin dosing protocol.Am J Health Syst Pharm. 1998; 55: 159-162
- Use of a modified dosing weight for heparin therapy in a morbidly obese patient.Ann Pharmacother. 2005; 39: 753-756
- Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight based dosing of unfractionated heparin: a retrospective cohort study.Mayo Clin Proc. 2009; 84: 1073-1078
- Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.Circulation. 2003; 107: 2884-2888
- Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.Pharmacotherapy. 2010; 30: 105e-112e
- An approach to venous thromboembolism prophylaxis in laparoscopic roux-en-y gastric bypass surgery.Obes Surg. 2004; 14: 731-737
- Prevention of venous thromboembolism American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition).Chest. 2008; 133: 381S-453S
- Efficacy and safety of recombinant human activated protein C for severe sepsis.N Engl J Med. 2001; 344: 699-709
- Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis.Ann Pharmacother. 2005; 39: 262-267
- Argatroban [package insert].GlaxoSmithKline, Research triangle park, NC2005
- Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIb/IIIa receptor antagonist in patients undergoing percutaneous coronary intervention.J Clin Pharmacol. 2004; 44: 981-990
- Effect of body mass index on argatroban therapy during percutaneous coronary intervention.J Thromb Thrombolysis. 2008; 25: 273-279
- Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia.J Clin Pharmacol. 2007; 47: 1028-1034
- Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected confirmed heparin-induced thrombocytopenia.Ann Pharmacother. 2009; 43: 19-27
- “Getting the dose right”: facts a blueprint and encouragements.Clin Pharmacol Ther. 2007; 82: 2-14
- Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects.Ther Drug Monit. 1986; 8: 189-194
- Antibiotic prophylaxis for surgery in morbidly obese patients.Surgery. 1989; 106: 750-757
- Antimicrobial dosing consideration in obese patients.Pharmacotherapy. 2007; 27: 1081-1091
- Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.Ann Pharmacother. 2007; 41: 1734-1739
- Pharmacodynamics of cefepime in patients with gram-negative infections.J Antimicrob Chemother. 2002; 50: 425-428
- Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.Antimicrob Agents Chemother. 2006; 50: 1222-1227
- Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.Ann Pharmacother. 2005; 39: 427-432
- In vivo pharmacodynamics of a new oxazolidinone (linezolid).Antimicrob Agents Chemother. 2002; 46: 3484-3489
- The pharmacokinetics of daptomycin in moderately obese, morbidly obese and matched nonobese subjects.J Clin Pharmacol. 2005; 45: 48-56
- Daptomycin.Pharmacotherapy. 2004; 24: 41-57
- Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.Antimicrob Agents Chemother. 2007; 51: 2741-2747
- Intravenous ciprofloxacin disposition in obesity.Clin Pharmacol Ther. 1993; 53: 368-373
- Intravenous ciprofloxacin dosing in morbidly obese patient.Ann Pharmacother. 1994; 28: 806
- Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society Health-System pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.Am J Health Syst Pharm. 2009; 66: 82-98
- Anesthesia in the obese patient: pharmacokinetic considerations.J Clin Anesth. 2005; 17: 134-145
Article info
Footnotes
The authors had no financial support to disclose.
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
